Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Overview
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Companies Involved in Therapeutics Development
Atlantic Healthcare Plc
Chi Medical System Holdings Ltd
Phio Pharmaceuticals Corp
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Drug Profiles
alicaforsen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Ri Oligonucleotide to Inhibit ICAM-1 for Oncology and Retil Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMS-024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNP-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target ICAM-1 for Aplastic Thyroid Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MS-553 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Dormant Products
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Discontinued Products
Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) - Product Development Milestones
Featured News & Press Releases
Jul 31, 2019: Atlantic Healthcare announces results from Phase 3 Trial of Alicaforsen Enema for Orphan-Desigted Pouchitis
May 01, 2019: Atlantic Healthcare to attend Digestive Diseases Week in San Diego, May 18-21
Nov 12, 2018: Atlantic Healthcare to present a poster at the Crohns & Colitis Foundation IBD: Innovate conference in New York on Tuesday, November 13, 2018
Nov 12, 2018: Atlantic Healthcare to present at the Stifel 2018 Healthcare Conference in New York
Sep 27, 2018: Atlantic Healthcare reports results from Phase 1 trial of tablet for Crohn’s
Sep 13, 2018: Atlantic Healthcare secures acceptance of brand me Camligo for alicaforsen enema to treat pouchitis
Aug 02, 2018: Strategic appointment expands Atlantic Healthcare executive team
May 02, 2018: Atlantic Healthcare completes patient enrollment to its Phase 3 study of alicaforsen to treat IBD Pouchitis
Jan 08, 2018: Atlantic Healthcare is attending the JP Morgan Healthcare Conference and the Crohn’s and Colitis Congress
Nov 08, 2017: Atlantic Healthcare to present at the Stifel 2017 Healthcare Conference in New York on November 15, 2017
May 30, 2017: Atlantic Healthcare develops tablet formulations of alicaforsen to treat Crohn’s disease and Ulcerative Colitis
May 22, 2017: Atlantic Healthcare announces strengthening of the Board as it prepares for commercialisation of alicaforsen in its first indication
May 01, 2017: Atlantic Healthcare initiates FDA rolling submission of its New Drug Application for alicaforsen in the treatment of pouchitis
Apr 24, 2017: Atlantic Healthcare appoints Durbin as Nordic regions distributor of alicaforsen under the med Patient Programme
Apr 02, 2017: Cell therapy provides shot at a cure for fatal thyroid cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Atlantic Healthcare Plc, H2 2019
Pipeline by China Medical System Holdings Ltd, H2 2019
Pipeline by Phio Pharmaceuticals Corp, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019